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Introduction: Management of infections with carbapenem-resistant Enterobacteriaceae (CRE) 
is challenging. In recent times, agents such as colistin and fosfomycin have been used in com-
bination with other antibiotics to treat such infections. In this study, we aim to seek frequency 
of colistin and fosfomycin resistance in CRE from Pakistan.
Methods: This study was conducted at clinical laboratories, Aga Khan University Hospital. In 
total, 251 CRE were included in the study. Colistin minimum inhibitory concentrations (MICs) 
were performed using broth microdilution (BMD) method and  VITEK® 2 system, whereas 
fosfomycin susceptibility was performed using Kirby–Bauer method. MIC
50
 and MIC
90
 were 
calculated for colistin and agreement between VITEK and BMD was also calculated.
Results: Out of 251 strains colistin MIC of ≥4 µg/mL was seen in 40 (15.9%). Of these strains 
20 (50%) were Klebsiella pneumoniae. Colistin MIC
50
 and MIC
90
 were found to be 0.5 and 
16 µg/mL, respectively. BMD and VITEK 2 showed 100% categorical agreement. Essential 
agreement was 88.5% with kappa score 0.733 indicating strong agreement between VITEK 
and BMD. 31 out of 251 (12.3%) CREs were resistant to fosfomycin.
Conclusion: Study shows frequency of colistin and fosfomycin resistance to be 15.9% and 
12.3%, respectively. In countries where rate of CREs is high, emerging resistance against these 
last resort antibiotics is alarming as it leaves clinicians with almost no options to manage such 
multidrug resistant and extensively drug resistant infections.
Keywords: emerging drug resistance, colistin resistance, fosfomycin resistance, carbapenam 
resistant enterobacteriaceae, salvage antibiotics
Introduction
Carbapenem-resistant Enterobacteriaceae (CRE) are increasingly being identified 
worldwide and pose a major threat to the treatment of infectious diseases and to infec-
tion control within heath care facilities.1 In 2014, a meta-analysis showed mortality rates 
attributable to CRE to be 26%–44%.2 Frequency of CRE is increasing in worldwide.3,4 
In Pakistan, the rates have been increasing steadily, data from our hospital showed 
increase in carbapenem-resistant Escherichia coli, Enterobacter spp. and Klebsiella 
pneumoniae from 5%, 7% and 15% in 2013 to 6%, 23% and 22% by 2015, respectively.5
With increasing antimicrobial resistance and given the paucity of new drugs, 
the focus of management has shifted to older agents.6 Currently, such antibiotics in 
use in Pakistan include colistin and fosfomycin. It has earlier been shown that treat-
ment of CRE with combination of carbapenem and colistin is associated with better 
outcomes7 leading to increased use of colistin in clinical practice.8 Fosfomycin has 
traditionally been used to treat urinary tract and gastrointestinal infections. A meta-
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analysis including 62 studies, showed utility of fosfomycin 
either alone or in combination with other antibiotics for 
the treatment of pneumonia, osteomyelitis, meningitis, ear, 
nose, throat infections and gynecological infections,9 hence, 
identifying fosfomycin as having potential for treatment 
of invasive infections. In February 2010, intravenous (IV) 
fosfomycin was prospectively evaluated for the treatment of 
carbapenem-resistant K. pneumoniae wherein all patients 
had bacteriological clearance with no adverse reactions.10
Given rising antimicrobial resistance and reports of CRE, 
this study was designed to evaluate the frequency of colistin 
and fosfomycin resistance in carbapenem-resistant Gram-
negative bacterial infections in our population.
Materials and methods
Study setting
This was a prospective study conducted on archived bacte-
rial isolates from clinical specimens received in the Clinical 
Microbiology Laboratory, Aga Khan University. The archived 
strains were stored at −80°C in glycerol phosphate broth and 
were revived on MacConkey agar before use.
Bacterial isolates
All CRE isolated from January 2015 to August 2016 were 
included. CREs were defined using CLSI 2015 cut-offs 
for ertapenem, imipenem or meropenem.11 Identification 
of strains included in the study was done using API 20E 
system. Strains with inherent resistance to colistin such as 
those belonging to genus Proteus, Providencia and Serratia 
were excluded from the study.
•	 Susceptibility testing: Carbapenem susceptibilities were 
performed by disc diffusion (Kirby–Bauer) method on 
Mueller Hinton agar11 and by VITEK 2 system.12 Isolates 
were labeled as CREs by disc diffusion zone diameters 
and by VITEK minimum inhibitory concentrations 
(MICs). For interpretation CLSI 2015 breakpoints for 
imipenem, ertapenem and meropenem, that is, for ertape-
nem disc diameter ≤19 mm or MIC ≥1, for imipenem 
and meropenem disc diameter ≤21 mm or MIC ≥2 were 
used.11
•	 Colistin susceptibility was performed as follows: broth 
microdilution using 96-well microtiter plates to perform 
MICs using cation adjusted Mueller Hinton broth as 
culture medium. Drug concentration ranging from 0.03 
to 16 µg/mL was used. MICs were performed in batches 
of 10−20 strains per batch, 5 days a week from July 2016 
till August 2016 on archived strains. Colistin sulfate 
powder was obtained from Sigma-Aldrich Co. (St Louis, 
MO, USA). ATCC E. coli 25922 and ATCC P. aeruginosa 
27853 were used as quality control strains. Results were 
read at 24 hours and interpreted using colistin cut-offs 
for Enterobacteriaceae in EUCAST 2016, that is, MIC ≤2 
as sensitive.13 Colistin MICs were also determined using 
automated VITEK 2 system. Results were compared with 
broth microdilution. Broth microdilution was used as the 
gold standard. Agreement between broth and VITEK was 
calculated.
•	 Fosfomycin susceptibility was tested by disc diffusion 
method using fosfomycin trometamol disc (200 µg) 
(Thermo Fisher Scientific, Waltham, MA, USA) contain-
ing 50 µg G6PD on Muller Hinton agar. Results were 
interpreted using CLSI 2015 disc diffusion cut-offs for 
E. coli in urinary tract isolates, that is, ≥16 as sensitive, 
13–15 intermediate and ≤12 as resistant.11
Ethical approval
As this study was conducted on archived bacterial isolates 
and not on patients’ samples, it was given exemption by the 
ethical review committee Aga Khan University Hospital 
(ERC# 3992-PAT-ERC-16).
Statistical analysis
Data entered in Microsoft Excel 2010® and imported to Stata 
SE (version 12) was used to calculate MIC
50
 and MIC
90
. 
MIC
50
 and MIC
90
 were defined as the lowest concentration 
of the antibiotic at which 50% and 90% of the tested strains 
were inhibited. Categorical and essential agreement between 
VITEK and broth microdilution was calculated using Kappa 
scores.
Results
The study included 251 strains. These included E. coli 
39.04% (98/251) followed by K. pneumoniae 31% (78/251), 
Raoultella spp. 15.5% (Raoultella terrigena and Raoultella 
ornithinolytica) (39/251), Enterobacter spp. 7.5% (19/251), 
Klebsiella oxytoca 5.1% (13/251) and Citrobacter spp. 
1.1% (3/251). Details regarding source and characteristics 
of patients from whom these isolates were obtained are 
provided in Table S1.
MIC50 and MIC90
Colistin MICs by broth microdilution was performed on all 
strains. MIC
50
 value was calculated to be 0.5 µg/mL, whereas 
MIC
90
 was 16 µg/mL. MIC
50 
and MIC
90 
values among dif-
ferent bacterial species was separately calculated (Figure 1).
Colistin MICs was ≥4 µg/mL in 40 out of 251 (15.9%) 
study strains which were identified as being colistin resistant. 
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Out of these 40 strains 50% were K. pneumonia (n: 20), 
22.5% R. terrigena (n:10), 10% Enterobacter spp. (n:4), 
7.5% E. coli (n:3) and 7.5% K. oxytoca (n:3).
Agreement between VITEK and broth
VITEK MICs were available for 149 strains and agreement 
was calculated. Broth and VITEK showed 100% categorical 
agreement with kappa score of 1, CI (0.84–1.16). Essential 
agreement was calculated to be 88.59% with kappa score of 
0.7334, CI (0.6–0.798).
Fosfomycin susceptibility
Among this CRE collection, rate of fosfomycin resistance 
was 12.3% (31/251). In the colistin-resistant CRE subgroup 
(n:40) 35 out of 40 remained susceptible to fosfomycin while 
5 stains were found resistant to both colistin and fosfomycin 
simultaneously.
Discussion
Multidrug resistant (MDR) and extensively drug resistant 
(XDR) bacteria are a global threat. In countries with limited 
resources, over-stretched health systems make it difficult to 
manage such infections. Furthermore, inadequate imple-
mentation of infection control policies contribute toward 
dissemination of both nosocomial infections as well as of 
antimicrobial resistance.
Our study showed 15.9% colistin and 12.3% fosfomycin 
resistance among CREs. Both colistin and fosfomycin are 
salvage antibiotics for treating MDR and XDR infections. 
Hence emerging resistance against these agents significantly 
reduces available treatment options. Despite their potential 
side effects and high cost, in the absence of alternatives, 
clinicians have had no option but to use these antibiotics.
Aga Khan University hospital is a 680-bedded tertiary care 
hospital which caters to thousands of patients all year round. 
Our laboratory has more than 200 collection units and par-
ticipates in external quality assurance surveys from College 
of American Pathologist on regular basis. Since rate of CRE 
in the hospital has been increasing over time, colistin or fos-
fomycin are only prescribed for patients on clinician’s advice 
and their use is closely monitored by the pharmacy service. 
As per Antibiotic policy of the hospital, IV fosfomycin and 
colistin have been labeled as restricted and controlled antibi-
otics which require mandatory approval from the infectious 
diseases pharmacist or ID physician for dispense.
Colistin resistance among CRE has been previously 
reported. Most of these studies have been case reports or out-
breaks in hospital settings. An outbreak in three institutions 
in Detroit, MI, USA reported a cluster of colistin-resistant, 
carbapenem-resistant K. pneumoniae infection in 2009.14 
Another study from Italy also reported emergence of colistin 
resistance in carbapenem-resistant K. pneumoniae strains 
Figure 1 Groups of Enterobacteriaceae with MIC ranges from 0.03 to 16 μg/mL.
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 collected from 21 hospital laboratories during November 
2013 to April 2014.15 Goel et al reported emergence of a 
cluster of 24 cases of colistin resistant K. pneumoniae in 
oncology unit in India.16
Earlier, colistin resistance was known to be mediated by 
chromosomal mutations which altered the lipopolysaccha-
ride of the bacterial outer membrane. These include mgrB, 
phoP/phoQ, pmrA, pmrB, pmrC, and crrABC.17 In 2015, a 
study from China reported emergence of plasmid mediated 
colistin resistance (mcr-1) in E. coli and K. pneumoniae 
from human and animals.18 A variant of mcr-1 (mcr-1.2) and 
mcr-2 were also detected in Italy and Belgium.19,20 Rapid rise 
of resistance in such a brief period is alarming and poses a 
major threat in countries with high CRE prevalence such as 
Pakistan, further minimizing available antibiotic options for 
treatment of CRE infections.
Due to excessive and inappropriate use of colistin, resis-
tance has not only emerged among CRE but other bacterial 
species as well. In 2002, an outbreak of colistin-resistant 
Pseudomonas aeruginosa in a pulmonology unit in the UK 
created an infection control concern,21 over the years this was 
followed with different reports from Australia, India and Iran 
where colistin resistance was documented in Acinetobacter 
baumanii as well.22–24
With limited available options for treating CRE infec-
tions, fosfomycin held promise. An earlier study on 152 MDR 
(including 85 XDR) Enterobacteriaceae isolates, reported 
overall susceptibility against fosfomycin of 92.8% (141/152).25 
These findings concurred with another study published in 
the same year, 2009, reporting 7% fosfomycin resistance in 
prospectively collected 68 K. pneumoniae isolates of which 
23 were also nonsusceptible to tigecycline and/or colistin.26 A 
recent study from Germany in 2013 tested fosfomycin against 
CRE and reported 78% of the tested strain as fosfomycin sen-
sitive.27 Hence, our data reporting 12.3% resistance in CRE 
suggests increasing resistance against this antibiotic.
Our study has few limitations. Due to financial constrain 
test strains were only identified on basis of biochemical iden-
tification using API 20E. Neither molecular identification of 
the isolates, nor resistance gene detection was performed for 
mcr-1, mrgB or other mutations. Hence additional studies are 
required to identify genetic mutations associated with colistin 
resistance in this part of the world. As we tested colistin and 
fosfomycin using two different methods (broth microdilution 
and disc diffusion) we could not look for synergism and, there-
fore, further studies are needed to evaluate synergy between 
different antibiotics combination for the treatment of CRE.
Conclusion
Our data suggest emerging in vitro resistance against colistin 
and fosfomycin in CREs from Pakistan. Our findings suggest 
a need for regular monitoring of antimicrobial resistance in 
the country including for colistin and fosfomycin. Our data 
further highlights the urgency for developing and imple-
menting a national policy toward control of antimicrobial 
resistance in Pakistan.
Disclosure
The authors report no conflicts of interest in this work.
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Supplementary material
Table S1 General characteristics of the bacterial isolates 
included in the study
General characteristics of the study N=251
Mean, age 50.9 years
Gender
Male (%) 56.8
Female (%) 43.13
Site of organism recovery
Urine 143
Blood 61
Cerebrospinal fluid 4
Pus 11
Tissue 7
Respiratory specimen 14
Other body fluids 11
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